[{"indications": "Indications\u00a0see under Dose", "name": "FLUCONAZOLE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.2 Antifungal drugs", "5.2.1 Triazole antifungals", "FLUCONAZOLE"], "cautions": "Cautions\u00a0concomitant use with hepatotoxic drugs, monitor liver function with high doses or extended courses\u2014discontinue if signs or symptoms of hepatic disease\r\n(risk of hepatic necrosis); susceptibility\r\nto QT interval prolongation; interactions: Appendix 1 (antifungals, triazole)", "side-effects": "Side-effects\u00a0nausea, abdominal discomfort, diarrhoea, flatulence,\r\nheadache, rash (discontinue treatment or monitor closely if infection\r\ninvasive or systemic); less frequently dyspepsia, vomiting, taste\r\ndisturbance, hepatic disorders, hypersensitivity reactions, anaphylaxis,\r\ndizziness, seizures, alopecia, pruritus, toxic epidermal necrolysis,\r\nStevens-Johnson syndrome (severe cutaneous reactions more likely in\r\nHIV-positive patients), hyperlipidaemia, leucopenia,\r\nthrombocytopenia, and hypokalaemia reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/127970.htm", "doses": ["Vaginal candidiasis (see also Recurrent Vulvovaginal Candidiasis, section 7.2.2) and\r\ncandidal balanitis, adult and child over 16 years, by mouth, a single\r\ndose of 150\u00a0mg", "Mucosal candidiasis (except genital), by mouth, 50\u00a0mg daily (100\u00a0mg daily in unusually difficult infections) given\r\nfor 7\u201314 days in oropharyngeal candidiasis (max. 14 days except in\r\nseverely immunocompromised patients); for 14 days in atrophic oral\r\ncandidiasis associated with dentures; for 14\u201330 days in other mucosal\r\ninfections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary\r\ninfections); child by mouth or by intravenous infusion, 3\u20136\u00a0mg/kg\r\non first day then 3\u00a0mg/kg daily (every 72 hours in neonate up to 2 weeks old, every 48 hours in neonate\r\n2\u20134 weeks old)", "Tinea pedis, corporis, cruris, pityriasis versicolor, and dermal\r\ncandidiasis, by mouth, 50\u00a0mg daily for 2\u20134 weeks (for\r\nup to 6 weeks in tinea pedis); max. duration of treatment 6 weeks", "Invasive candidal infections (including candidaemia and disseminated\r\ncandidiasis) and cryptococcal infections (including meningitis), by mouth or intravenous infusion, 400\u00a0mg on first day then 200\u2013400\u00a0mg daily; max. 800\u00a0mg daily in\r\nsevere infections [unlicensed dose]; treatment continued according\r\nto response (at least 8 weeks for cryptococcal meningitis); child 6\u201312\u00a0mg/kg daily (every 72 hours in neonate up to 2 weeks old, every 48 hours in neonate 2\u20134 weeks old); max. 800\u00a0mg daily [unlicensed\r\ndose]", "Prevention of relapse of cryptococcal meningitis in HIV-infected\r\npatients after completion of primary therapy, by mouth or by intravenous infusion, 200\u00a0mg\r\ndaily", "Prevention of fungal infections in immunocompromised patients, by mouth or by intravenous infusion, 50\u2013400\u00a0mg daily adjusted according to risk; 400\u00a0mg daily if high\r\nrisk of systemic infections e.g. following bone-marrow transplantation;\r\ncommence treatment before anticipated onset of neutropenia and continue\r\nfor 7 days after neutrophil count in desirable range; child according to extent and duration of neutropenia,\r\n3\u201312\u00a0mg/kg daily (every 72 hours in neonate up to 2 weeks old, every 48 hours in neonate 2\u20134 weeks old); max. 400\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid\u2014multiple congenital abnormalities\r\nreported with long-term high doses"}]